PODXL and cancer: We have developed CasMabs against HER2 (H2Mab-250 [33,34]), podocalyxin (PcMab-6 [35]), and podoplanin (LpMab-2 [36] and LpMab-23 [37]) by evaluating the reactivity against cancer and normal cells in flow cytometry and immunohistochemistry.